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Abstract
Background: Cardiovascular risk (CVR) has been observed to be higher in patients with severe mental illness (SMI)
than in the general population. However, some studies suggest that CVR is not equally increased in different
subgroups of SMI. The purposes of this review are to summarise CVR scores of SMI patients and to determine the
differences in CVR between patients with different SMIs and between SMI patients and the control-population.
Methods: MEDLINE (via PubMed) was searched for literature published through August 28, 2014, followed by a
snowball search in the Web of Science. Observational and experimental studies that reported CVR assessments in
SMI patients using validated tools were included. The risk of bias was reported using STROBE and CONSORT criteria.
Pooled continuous data were expressed as standardized mean differences (SMD) with 95 % confidence intervals
(CI). Two reviewers independently selected studies, extracted data and assessed methodological quality.
Results: A total of 3,608 articles were identified, of which 67 full text papers were assessed for eligibility and 35
were finally included in our review, in which 12,179 psychiatric patients and 225,951 comparative patients had been
assessed. The most frequent diagnoses were schizophrenia and related diagnoses (45.7 %), depressive disorders
(14.7 %), SMI (11.4 %) and bipolar disorders (8.6 %). The most frequent CVR assessment tool used was the
Framingham risk score. Subgroups analysis showed a higher CVR in schizophrenia than in depressive disorder or in
studies that included patients with multiple psychiatric diagnoses (SMD: 0.63, 0.03, and 0.02, respectively).
Six studies were included in the meta-analysis. Total overall CVR did not differ between SMI patients and controls
(SMD: 0.35 [95 % CI:−0.02 to 0.71], p = 0.06); high heterogeneity was observed (I2 = 93 %; p < 0.001).
Conclusions: The summary of results from studies that assessed CVR using validated tools in SMI patients did not
find sufficient data (except for limited evidence associated with schizophrenia) to permit any clear conclusions
about increased CVR in this group of patients compared to the general population.
The systematic review is registered in PROSPERO: CRD42013003898.
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Background
Cardiovascular disease is the leading cause of overall
mortality, accounting for 24 % of deaths worldwide, while
psychiatric diseases, led by major depressive disorder, are
considered the eleventh most burdensome disease glo-
bally, with an increasing effect on overall mortality [1, 2].
Criteria for the definition of severe mental illness
(SMI) differ, with some authors applying a narrow defin-
ition based on psychosis [3] and others also including a
set of nosological entities of different types and clinical
symptoms but with several common diagnostic criteria:
severity, persistence over time (2 years or more), and a
tendency toward clinical deterioration and difficulties in
social and occupational function [4, 5].
It has been reported that cardiovascular risk (CVR)
is higher in patients with SMI [6]. Studies in patients
with bipolar disorder and schizophrenia indicate that
they have a higher CVR than in the general popula-
tion [7]. In patients with schizophrenia, the most
prevalent CVR factors are hyperlipidaemia (61 %),
smoking (55 %), obesity (41 %), diabetes (19 %) and
hypertension (17 %)) [8]. Risk of metabolic syndrome
is also higher among patients with schizophrenia and
bipolar disorder [9]. Moreover, patients with anxiety
and major depression have higher prevalence of
hypertension compared to groups of similar age from
the general population [10, 11].
Several factors may contribute to this raised CVR
among patients with SMI, including unhealthy behav-
iours, difficulties in communication, barriers to medical
care, poor treatment adherence and social deprivation
[12]. Patients with SMI often receive fragmented medical
care and fewer preventive measures, which leads to
higher levels of underdiagnosis and lower rates of
disease control [13]. Furthermore, antipsychotic drugs,
antidepressants, and mood-stabilizing drugs have dele-
terious side effects, including important cardiometabolic
consequences [14–16].
However, to date no systematic analysis has investi-
gated whether CVR is increased equally in all patients
with SMI, making it difficult to design and implement
effective, feasible, evidence-based interventions for CVR
management in these patients. A summary of the obser-
vations about CVR in the different subgroups of patients
with SMI would provide a better epidemiological
description of the problem, inform more effective clin-
ical and preventive strategies and help in the design of
further studies.
The major aim of this review was to summarize the
available evidence of CVR scores in patients with SMI.
Furthermore, this review attempted to determine
whether CVR differs between subgroups of SMI patients
and compare the CVR between patients with SMI and
the general or non-psychiatric population.
Methods
The Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) criteria were used to under-
take this review and meta-analysis [17], together with
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) [18]. We conducted a system-
atic review of studies that reported CVR in patients with
SMI.
Eligibility criteria
We included studies that reported CVR scores in patients
with SMI. The following 10 diagnoses were included in
the search strategy (Table 1): schizophrenic disorders,
schizotypal disorders, persistent delirious disorders, in-
duced delirious disorders, schizoaffective disorders, other
non-organic psychotic disorders, bipolar disorder, serious
depressive episode with psychotic symptoms, recurrent
serious depressive disorders, and compulsive obsessive
disorder [5].
We included observational and experimental studies
that applied validated CVR tools, including Framing-
ham risk score (FRS) with its subtypes of scores
(cardiovascular disease (CVD), cardiovascular heart
disease (CHD), Myocardial infarction (MI) and the
Systematic Coronary Risk Evaluation (SCORE). If the
studies reported data on other CVR scores not de-
scribed above, these were also included.
We excluded articles that were based on first episodes
of SMI, different reports from the same population
Table 1 Search strategies for the electronic databases (data retrieved August 28, 2014)
Database Search Strategy References
PubMed ("Psychotic Disorders"[Mesh] OR "Bipolar Disorder"[Mesh] OR "Schizophrenia"[Mesh] OR psychotic OR psychosis
OR psychoses OR schizo* OR bipolar OR manic OR mania OR delirious OR depress* OR obsessive-compulsive OR
"obsessive compulsive" OR “compulsive obsessive” OR OCD OR agoraphob* OR panic OR phobia OR phobic OR
melanchol* OR neurosis OR neurotic OR neuroses OR conversion disorder* OR “Mental Disorders” OR “severe
mental”) AND (cardiovascular OR “Cardiovascular diseases” OR CVD) AND (risk score* OR risk chart* OR “risk
prediction” OR risk check* OR “risk assessment” OR “risk evaluation” OR “risk calculator” OR risk-estimation OR
“risk estimation” OR "year risk" OR “year CVD risk” OR Framingham OR “SCORE risk” OR SCORE chart* OR SCORE
table*OR “Systematic Coronary Risk Evaluation” OR “REGICOR” OR “REGICOR table”* OR ASSIGN OR QRISK OR
PROCAM OR WHO/ISH)
653
Web of Science Snowballing: references cited in the eligible papers (forward), and references citing the eligible papers (backward) 2,955
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(selecting the study with the most recent publication
date or the largest sample size), papers reporting diagno-
ses based on symptoms, and studies referring to one or
two psychotropic drugs.
Search strategy
We conducted a systematic search in PubMed using a
combination of MESH and free text terms (Table 1). We
searched from inception to the August 28, 2014. Based
on the articles selected, we performed a snowball search
in the Web of Science. We reviewed all the references
(backward search) and the articles that cited the in-
cluded papers (forward search). In addition, we added
articles that were identified during the implementation
of the review (hand searching). There were no language
restrictions.
Study selection
Two researchers (CVF and QFB) reviewed the titles and
abstracts of all studies identified in the initial search and
defined a list of full text articles to be assessed. Cases of
discordance were resolved by consensus; when neces-
sary, the full-text article was reviewed. We conducted a
pilot test of the eligibility criteria on a sample of 15 arti-
cles. We used this test to clarify these criteria and ensure
that they were applied consistently by all reviewers.
Primary outcome was the CVR assessed with any vali-
dated CVR tool.
Data collection
We used a standardized data-collection form to record au-
thor and publication year, study design, country, setting,
diagnosis, diagnostic criteria, number of participants and
age in the psychiatric group and the comparative group (if
applicable) and the objective of the study.
To assess the methodological quality of the studies, we
used the Strengthening the Reporting of Observational
Studies in Epidemiology Statement (STROBE) checklist
for observational studies, with a maximum possible score
of 24 [19], and the Consolidated Standards of Reporting
Trials (CONSORT) for randomized trials, with a max-
imum possible score of 37 [20], giving one point for each
item the article addressed.
Two reviewers assessed methodological quality and
extracted the data independently. Discrepancies were re-
solved by consensus between the two reviewers (CVV
and QFB) and by discussion with a third reviewer (MFS)
as needed. Inter-rater agreement was 96 %.
Statistical analysis
We analysed outcomes using Review Manager (RevMan,
version 5.3). Pooled continuous data were expressed as
standardized mean differences (SMD) with 95 % confi-
dence intervals (CI). The effect size (ES) was categorized
as small (<0.2), small to moderate (0.2–0.5), moderate to
large (0.51–0.79), large (>0.79). Pooled SMD were esti-
mated by using an inverse-variance-weighted random-
effects model. Heterogeneity was quantified with the I2
statistic, which describes the proportion of the total
between-study variability due to heterogeneity [21]. We
used subgroup analysis to evaluate whether results dif-
fered according to the diagnosis (depressive disorder,
schizophrenia vs psychiatric diagnoses), diagnosis criteria
(non-specific (NE) vs DSM IV), study design (observa-
tional vs randomized control trial); and outcome (cardio-
vascular disease, coronary heart disease, stroke)
We assessed publication bias by using funnel plots. In
sensitivity analysis, we assessed the relative influence of
each study on the pooled estimate by omitting one study
at time.
Protocol and registration
The initial protocol of the review was submitted to the
International Prospective Register of Systematic Reviews
(PROSPERO, http://www.crd.york.ac.uk/PROSPERO/).
The definitive protocol included the modifications sug-
gested by the PROSPERO reviewers. The registration
number of systematic review is: CRD42013003898.
Results
The electronic and manual searches retrieved 3,608
articles, of which 67 full-text papers were assessed for
eligibility and 35 studies were finally included in our re-
view (Fig. 1), representing a total of 12,179 psychiatric
patients and 225,951 controls. Sample size of psychiatric
study groups ranged from 36 [22] to 1,942 [23] partici-
pants. Of the 35 studies, 19 studies in Eurasia (16 in
Europe) and 16 studies were conducted in the Americas.
The most common design was cross-sectional (22 stud-
ies); 8 studies were randomized controlled trials (RCT)
and only 5 were case-control studies (Table 2). A 45.7 %
of the studies were performed in secondary services ex-
clusively and 31.4 % in the hospital setting. The most
frequent diagnoses were schizophrenia and related diag-
noses (45.7 %), depressive disorders (14.3 %), and bipolar
disorders (8.6 %). Seven studies (20.0 %) included differ-
ent psychiatric diagnoses and only 4 (11.4 %) showed
data on SMI as a whole (Table 1).
In 30 studies, methodological quality was evaluated
with STROBE and most showed a high quality score
(median 21.00, SD: 6.40). Five were evaluated with
CONSORT and most had a low quality score (median
18.57, SD: 2.72). The STROBE evaluation revealed two
main weaknesses: insufficient efforts to address potential
sources of bias and sparse information for each variable
of interest on the number of participants with missing
data. The CONSORT weaknesses were the method used
to generate the random allocation sequence and type of
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randomisation; details of any restriction (such as
blocking and block size); and information about where
the full trial protocol can be accessed, if available
(Additional file 1: Appendix 1).
Of the 35 studies included, only 7 studies had con-
trol groups [22, 24–29]. These studies used different
scores to evaluate CVR (Table 2). Three studies in-
cluded only patients with schizophrenia and controls:
two studies were based on FRS (CVD) scores: 10.7 vs.
8.5 p ≤ 0.01 [28] and 4.7 (4.7) vs. 3.1 (3.2), p = 0.002
[29] and one was based on FRS (CHD) scores: 8.6
(7.3) vs. 6.3 (6.0), p < 0.001 [24]. Two studies included
psychiatric diagnoses and were based on FRS (CVD)
scores: 11.3 (12.3) vs. 6.8 (6.4), p < 0.01 [25] and 8.3
(5.8) vs. 10.7 (5.9), p = 0.05 [26]. One study included
depressive disorders: 10.3 (7.6) vs. 10.1 (7.7), p = 0.97
[22]. One study had insufficient data and was not in-
cluded in the meta-analysis.
Table 3 synthesized the data about CVR scores
found in studies by diagnosis groups of diseases. The
CVR mean score assessed with FRS (CVD) in patients
with depression ranged from 5.8 to 14.0, in patients
with schizophrenia from 4.7 to 11.9, and was 13.7 in
the only study of patients with bipolar disorder. Stud-
ies that addressed patients with SMI reported that
CVR had been expressed in different forms (Table 3).
Subgroup analysis was performed in six studies (3
involving schizophrenia, 1 depressive disorder and 2
psychiatric diagnoses in general). Higher CVR was ob-
served in patients with schizophrenia than in those with
depressive disorder or general psychiatric diagnosis,
with a pooled SMD (95 % CI) as follows: 0.63 (0.16,
1.09), 0.03 (−0.48, 0.54), and 0.02 (−0.82, 0.86), respect-
ively (Table 4). The sensitivity analysis omitted one
study at a time, showing a pooled SMD ranging from
0.19 to 0.50. Funnel plots did not suggest any publica-
tion bias (Additional file 2: Appendix 2).
Six studies that included 1,065 people with SMI who had
a CVR assessment and 1,567 people without SMI were in-
cluded in the meta-analysis [22, 24–27, 29]. The total over-
all CVR between the psychiatric group and control group
showed a SMD of 0.35 (95 % CI:−0.02–0.71, P = 0.06) with
significantly high heterogeneity (I2 = 93 %; p < 0.001)
(Fig. 2).
Fig. 1 Flow diagram of article review process
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Table 2 Characteristics of the studies included in the review
Author, year Study design Country Setting Diagnosis Diagnostic
criteria
Psychiatric Group Comparative Group
Number Age
[mean(SD)]

































































































































India Hospital Bipolar disorder ICD10 105 39.6 (13.1) 3.4 (5.0) 1.7 (1.8)
Hoffman BM,
2010 [55]
RCT USA H ospital Depressive
disorder























































































































118 53.0 (9.9) 13.7 (10.0)
Smith PJ,
2007 [63]
RCT USA Not reported Depressive
disorder


































DSM IV 352 70.7 (7.4) 5.8 (3.8)
Abbreviations: FRS Framingham risk score, CVD cardiovascular disease, CHD cardiovascular heart disease, MI myocardial infarction, SCORE systematic coronary risk evaluation, NE: SMI severe mental illness, DSM-IV











Table 3 Cardiovascular risk assessment by diagnostic group (depressive, bipolar, SMI and schizophrenia)
Diagnosis Groups Author, year Psychiatric Group Notes




Grover S, 2014 [54] 3.4 (5.0) 1.7 (1.8)
Slomka JM, 2012 [62] 13.7 (10.0)
Garcia-Portilla MP, 2009 [52] 7.6 (7.4) 1.8 (4.4)
Depressive
disorder
Acharya T, 2013 [43] FRS (CHD) expressed by types of
antidepressive medication groups.
Allan CL, 2011 [22] 10.3 (7.6)
Hoffman BM, 2010 [55] 14.0 (9.0)
Smith PJ, 2007 [63] 3.2
Zuidersma M, 2015 [66] 5.8 (3.8)
Schizophrenia Bernardo M, 2009 [45] SCORE: <1 %: 15.1 %; 1–4 %:68.8 %; 5–10 %:
6.1 %; 11–15 %:0.3 % and ≥15 %;0.1 %
Daumit GL, 2008 [48] 8.5 (7.4)
Ferreira L, 2010 [51] SCORE: no statistically significant difference
between case and controls was observed.
Goodrich DE, 2012 [53] FRS (CVD): <10 %: 40.7 %, 10–20 %: 40.7 %
and >20 %: 18.6 %
Goff DC, 2005 [24] FRS (CHD): In men: CATIE study: 9.4 (7.2);
NHANES study: 7.0 (6.3) and in women:
6.3 (6.3) and 4.2 (4.5), respectively.
McCreadie RG, 2003 [27] 4.1 9.6
Nurjono M, 2014 [57] FRS (CVD): Participants in the highest
quartile of serum BDNF had a 3.3 times
increased in FRS over those in the
lowest quartile.
Said MA, 2012 [59] 6.3 (5.6) 31.5 % of patients in the metabolic
syndrome group had a high/very high
FRS (CHD) vs. 11 % in non-metabolic
syndrome group (p < 0.001)
Tay YH, 2013 [29] 4.7 (4.7)
Protopopova D, 2012 [58] SCORE≥ 5 %: 10 %
Arango C, 2008 [44] 6.8 (6.9) 0.9 (1.9)
Cohn T, 2004 [37] FRS (MI): 8.9 % in males, compared with
control subjects (6.3) (p < 0.001) and 2.6 %
females (vs. Control subjects 2.0 %) (p = 0.180).
McLean G, 2014 [23] Joint British Societies score: risk levels by
age group and gender. Age was a major factor
being identified as high risk (>20 %), with 79 %
of those with schizophrenia aged 65–74 estimated
at high risk compared with only 1.3 % of those
aged 35–44.
Ratliff JC, 2013 [28] 10.7
Stroup TS, 2013 [60] 7.3 (5.7)
Sicras-Mainar A, 2013 [61] 11.9 (5.7)
SMI Dickerson FB, 2013 [49] FRS (CVD) in smokers 13.2 (11.9) and
nonsmokers 7.4 (7.2)
Druss BG, 2010 [50] FRS (CHD): 6.9 for intervention and 9.8 for
control group.
Foguet-Boreu Q, 2013 [32] FRS (REGICOR): high (≥10 %): 4.6 % and
SCORE: high (≥5 %): 5.4 %
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Discussion
Data from studies that reported CVR scores did not
support higher risk in patients with SMI than in the
control population. Subgroup analysis showed a higher
CVR associated with schizophrenia than with other
SMIs. Only in patients with schizophrenia was there
some evidence of higher CVR scores than in the control
population.
To date it has been widely accepted that the preva-
lence of modifiable risk factors was increased in patients
with SMI [30]. Nonetheless, several authors have sug-
gested that not all risk factors were equally increased in
these patients. A number of studies have found that
smoking and diabetes rates were higher in the SMI
population than in the reference population [31], while
others observed that hypertension was not increased
among SMI patients [31–33]. Conversely, other authors
did not detect significant differences in CVR factors be-
tween participants with and without SMI [34]. This
could be the result of publication bias affecting CVR
studies and therefore affecting CVR assessment. Chap-
man et al., in a meta-analysis of 42 studies on smoking
in patients with schizophrenia, revealed that studies
reporting low prevalence of this risk factor are cited less
often than those reporting higher prevalence in this
population [35].
Numerous previous studies have noted the importance
of CVR factors in patients with SMI, but only a few of
them incorporated CVR evaluation in the last 12 years.
No other systematic review has been found in the litera-
ture on this topic. However, Osborn et al., in a system-
atic review which objective was to determine the relative
risk of some CVR factors in people with SMIs, synthe-
sized data about some studies that reported 10 year car-
diovascular risk scores [31]. One controlled community
study, including 74 SMI patients found that excess CVR
scores showed that participants with SMI had higher
FRS (CHD) than participants without SMI (median 10-
year risk: 5 vs. 4 %) [36]. Another study, including 84
schizophrenic patients showed a significant increase of
CVR only in males based on FRS (CHD) (10.4 vs. 6.4 %)
[27]. And the last, involves 240 patients schizophrenia
and schizoaffective disorders showed also an increased
risk based on FRS (MI) score only in male patients com-
pared to controls (8.9 vs. 6.3 %) [37]. Our review also
Table 3 Cardiovascular risk assessment by diagnostic group (depressive, bipolar, SMI and schizophrenia) (Continued)
Osborn DP, 2006 [36] FRS (CHD): median: 5 % (IQR:2–12)
Psychiatric
diagnoses
Wysokiński A, 2012 [65] 6.4 (7.2) 3.7 (2.8) 5.8 (6.1)
Correll CU, 2006 [46] FRS (CHD): 8.29 (0.49) in men and 2.33 (0.52)
in women.
Jin H, 2011 [56] FRS (CHD) was increased by 79 % in
schizophrenia, 72 % in posttraumatic
stress disorder and 61 % in mood disorder.
Mackin P, 2007 [25] 11.3 (12.3) 1.7 (3.2) 9.3 (10.5)
Margari F, 2013 [26] 8.3 (5.8)
Correll CU, 2011 [47] 2.5 (4.2)
Taylor V, 2010 [64] FRS (CHD) was lower for patients at baseline
and follow-up, but increased across the follow-up
period (2-years). Women patients showed an
increase risk for CHD over time, and men did not.
Data are expressed as mean (SD), unless otherwise stated
Abbreviations: FRS Framingham risk score, CVD cardiovascular disease, CHD cardiovascular heart disease, MI myocardial infarction, SCORE systematic coronary risk
evaluation, SMI severe mental illness, PTSD posttraumatic stress disorder
Table 4 Stratified pooled standardized mean differences for
cardiovascular risk assessment
Number of studies SMD I2
(95 % CI)
Diagnosis
Depressive disorder 1 0.03 (−0.48, 0.54) 0 %
Schizophrenia 3 0.63 (0.16, 1.09) 94 %
Psychiatric diagnosis 2 0.02 (−0.82, 0.86) 92 %
Criteria for diagnosis
NE 1 0.35 (0.24, 0.45) 84 %
DSM IV 5 0.32 (−0.11, 0.75) 94 %
Study design
Observational study 5 0.34 (−0.21, 0.88) 94 %
RCT 1 0.35 (0.24, 0.45) 0 %
Outcome
CVD total 4 0.40 (−0.44, 1.02) 95 %
CHD 1 0.35 (0.24, 0.45) 0 %
Stroke 1 0.03 (−0.48, 0.54) 0 %
Abbreviations: SMD standardized mean difference, CI confidence interval, NE
non-specific, DSM IV statistical manual of mental disorders, RCT randomized
controlled trial, CVD cardiovascular disease, CHD coronary heart disease
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showed that schizophrenia is the group that have more
evidence of higher CVR than control groups and is con-
sistent with other studies [38, 39].
However, the discrepancy between data showing
higher CVR in SMI and the CVR assessment obtained
in our review raises some questions. The tools to meas-
ure CVR that have been validated for general popula-
tion may not apply to patients with SMI. In this sense,
Osborn et al. proposed a CVR prediction model for this
population [40]. In addition to the usual predictors, this
model also included social deprivation, heavy alcohol
use, SMI diagnosis, and prescriptions for antidepres-
sants and antipsychotics [40]. Another key point is the
influence of the prescribed medications on CVR. There
is strong evidence that antipsychotic drugs, and to a
more restricted degree antidepressants and mood stabi-
lizers, are associated with an increased risk for several phys-
ical diseases, including obesity, dyslipidaemia, diabetes
mellitus and so on [41]. Furthermore, unclear benefits of
different kinds of antipsychotics (first vs. second-generation
antipsychotics) have been reported [42], despite the super-
ior efficacy and greater treatment persistence attributed to
second-generation antipsychotics.
Our analysis showed that schizophrenia is the group at
highest risk, in consonance with other studies that showed
an increased risk in patients with schizophrenia and de-
pression, compared to other SMIs [41, 42]. Of the three
studies of schizophrenic patients included in the forest
plot summary, McCreadie et al. [27] clearly had the high-
est SMD. This difference may be explained by the inclu-
sion of older patients with a longer history of illness
compared to the other two studies [24, 29].
Strengths and weaknesses of this review
The major strength of this study is that it is the first
review to focus on CVR assessments in patients with
SMI. The search identified a large number of studies
(67) that showed CVR data. Osborn et al. centred
their attention on studies of CVR factors and also
showed results of CVR assessments provided by 4
studies, three of which included only schizophrenia
and related disorders; one study also included non-
affective chronic psychotic illness [31].
Our study also has a number of limitations to be taken
into account. We only searched a single data source, al-
though this limitation was countered by an extensive
manual search (snowball method). Furthermore, a large
number of studies had no control group, making it im-
possible to include them in the meta-analysis. Of the 7
studies with control groups [22, 24–29], only 6 had suffi-
cient data for inclusion in the meta-analysis and the het-
erogeneity of data synthesis was considerable (I2 > 75 %).
Therefore, all the conclusions of the meta-analysis
should be considered with caution. The variability of the
studies included in the meta-analysis could be attributed
to the ages of the participants, the diagnoses included,
and differences in study design.
Implications for future research
Further work is needed to establish whether patients with
SMI have increased CVR compared to general population.
More information on the type of CVR assessment used
would help to establish a greater degree of accuracy on this
question. A new risk assessment approach may be needed
in future studies in order to include other relevant factors
(obesity, psychotropic drugs and social deprivation) [38]. In
addition, a discussion is needed to reach consensus on an
operational definition of SMI that can be applied for re-
search purposes.
Conclusions
A review of literature reporting CVR assessment in
patients with SMI did not find sufficient evidence to
determine whether or not there is a higher risk in these
patients relative to the reference population. Subgroup
Fig. 2 Summary of forest plot. Standardized mean differences between psychiatric group and comparative group
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analysis showed a higher CVR in patients with schizo-
phrenia compared to those with depressive disorder or a
psychiatric diagnosis. Only in patients with schizophre-
nia was there some evidence of higher CVR scores than
in the control population. Instead of the generalized idea
that SMI is associated with increased CVR, it is import-
ant to consider the complexity of summarizing the data
because there is no universal definition of SMI or stand-
ard methods to describe CVR in this population. Further
work is needed to elucidate whether new CVR charts
that incorporate intrinsic determinants (as the effect of
psychotropic drugs or social deprivation) should be
established for risk assessment in this population.
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